A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts
about
Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic targetTMAinspiration: Decode Interdependencies in Multifactorial Tissue Microarray Data.Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail.Recent progress in protein profiling of clinical tissues for next-generation molecular diagnostics.Seq-ing improved gene expression estimates from microarrays using machine learning.SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.Revisiting determinants of prognosis in cutaneous melanoma.Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis.High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinomaMicrosomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression.Protein kinase PKN1 represses Wnt/β-catenin signaling in human melanoma cells.The role of Wnt/β-catenin signaling pathway in melanoma epithelial-to-mesenchymal-like switching: evidences from patients-derived cell lines.Construction and analysis of multiparameter prognostic models for melanoma outcomeTumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway.Melanoma metastasis: new concepts and evolving paradigms.Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.Immunology Comes Full Circle in Melanoma While Specific Immunity Is Unleashed to Eliminate Metastatic Disease, Inflammatory Products of Innate Immunity Promote Resistance.Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.Differential UBE2C and HOXA1 expression in melanocytic nevi and melanoma.Immunohistochemical analysis of T-type calcium channels in acquired melanocytic naevi and melanoma.Molecular pathology of cutaneous melanomaOncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
P2860
Q28393356-8E6E9245-4A2D-462E-BA61-BE8EFEAEFC61Q31113719-A3BBBA1C-A729-4C74-8533-4BF0C12EE33DQ34838275-AD8B896E-F867-416F-897F-B11090E12C75Q35714211-BD886E2D-5BE6-45B8-9A94-E1923029CF36Q35764271-519B10EA-3A3B-47B5-9A49-2059A8F57660Q36286668-A62B5064-12A8-4830-B167-B99B1B3E6AB4Q36338825-14EC3703-22A5-459C-BC74-BAA14E64DCCFQ36356155-D8912AD3-C1A9-491C-B686-9446B7DC76DCQ36632043-A2A0586E-A21B-4533-B7FC-0513FA50D068Q36823360-06E200B5-99C5-41ED-A686-47F66C71DD25Q37348939-F9CEC7BB-BD6B-4CDE-88A6-84E3F056E130Q37536551-22865A4F-A1E3-4EC9-93AC-9E7B76DE4EB9Q37550749-99465C6D-63B1-4CC1-B5F7-1263F1D7923DQ37585155-4F2921AF-4917-4F98-B036-CD754D2349E5Q37652928-1F24A0D4-28D5-4FCE-A2BF-F7826909D4DFQ38111220-42C30615-EB1F-413C-B6E5-5BB8A8360166Q38201655-977DFE1B-853A-4195-9541-508BB5983B28Q38459448-BE3372B1-F9E1-4575-9590-F43A05458116Q38788784-C325AB9C-45B7-4980-A883-A655398C2960Q39536215-BCEF90DD-37D4-4ABE-A8B4-14C239C48A3FQ41701119-791FD0F7-FA0C-4A55-BA56-17EEBB48253BQ46411728-276E6FEC-AD95-48B4-B9A9-14387E9119F2Q51777015-26C7F27B-6850-470A-AA25-DEE74CE6E3E4Q56428911-262AAF9F-1A26-4587-92CE-7A8E6B9EF5A2Q58024450-95C7B19E-66F9-4457-AD60-818D09379F6F
P2860
A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts
description
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
article publié dans la revue scientifique PLoS ONE
@fr
artículu científicu espublizáu en 2012
@ast
im Januar 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2012)
@en
vedecký článok (publikovaný 2012)
@sk
vědecký článek publikovaný v roce 2012
@cs
wetenschappelijk artikel (gepubliceerd in 2012)
@nl
наукова стаття, опублікована у 2012
@uk
name
A seven-marker signature and c ...... wo independent patient cohorts
@ast
A seven-marker signature and c ...... wo independent patient cohorts
@en
A seven-marker signature and c ...... wo independent patient cohorts
@nl
type
label
A seven-marker signature and c ...... wo independent patient cohorts
@ast
A seven-marker signature and c ...... wo independent patient cohorts
@en
A seven-marker signature and c ...... wo independent patient cohorts
@nl
prefLabel
A seven-marker signature and c ...... wo independent patient cohorts
@ast
A seven-marker signature and c ...... wo independent patient cohorts
@en
A seven-marker signature and c ...... wo independent patient cohorts
@nl
P2093
P2860
P3181
P1433
P1476
A seven-marker signature and c ...... wo independent patient cohorts
@en
P2093
Armin Pauer
Ferdinand Hofstädter
Holger Moch
Ingrid Moll
Joachim M Buhmann
Johanna M Brandner
Michael Landthaler
Nikos Anagnostou
Peter J Wild
Stefanie Meyer
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0038222
P407
P577
2012-01-01T00:00:00Z